Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate

Omacetaxine mepesuccinate (Synribo(®)) is an inhibitor of protein synthesis indicated for the treatment of patients with chronic- or accelerated-phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors. Myelosuppression is the most common and...

Descripción completa

Detalles Bibliográficos
Autores principales: Akard, Luke, Kantarjian, Hagop M., Nicolini, Franck E., Wetzler, Meir, Lipton, Jeffrey H., Baccarani, Michele, Khoury, H. Jean, Kurtin, Sandra, Li, Elizabeth, Munteanu, Mihaela, Cortes, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552050/
https://www.ncbi.nlm.nih.gov/pubmed/26436949
http://dx.doi.org/10.3109/10428194.2015.1071486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552050/
https://www.ncbi.nlm.nih.gov/pubmed/26436949
http://dx.doi.org/10.3109/10428194.2015.1071486

Ejemplares similares